Lv1
60 积分 2024-02-04 加入
Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee
29天前
已完结
Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
29天前
已完结
Targeting common EGFR mutations in non-small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors
29天前
已完结
Targeting MET in EGFR-mutated NSCLC
29天前
已完结
Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation
29天前
已完结
Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies
29天前
已完结
Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations
29天前
已完结
P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR –Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape
29天前
已完结
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?
1个月前
已完结
Safety and antitumor activity of the first-in-class EGFR-HER3 bispecific antibody-drug conjugate iza-bren (BL-B01D1) in patients with pretreated locally advanced or metastatic breast cancer: a phase 1b study
1个月前
已完结
皖公网安备34019202002308
